Task Force Overview
From LipidomicsWiki
(Difference between revisions)
Current revision (08:17, 21 July 2011) (view source) |
|||
(44 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
- | == | + | The LipidomicNet consortium consists of six vertical (TFI-VI) and three horizontal integrative (TFVII-TFIX) task forces.<br>Specific enabling technologies and their applications (TF I-IV).<br>Mouse models (TF V).<br>Human clinical trials and ethics issues (TF VI).<br>Translational research (TF VII).<br>LipidomicNet (TF VIII).<br>Dissemination and training (TF IX).<br> |
- | The following table shows an overview | + | |
- | {|class="prettytable" | + | == Overview of LipidomicNet Task Forces == |
+ | |||
+ | The following table shows an overview of the task forces their Leaders and corresponding LipidomicNet partners. | ||
+ | |||
+ | {| class="prettytable FCK__ShowTableBorders" | ||
+ | |- | ||
! Vertical Task Forces | ! Vertical Task Forces | ||
+ | |||
! Taskforce | ! Taskforce | ||
- | ! | + | |
- | ! | + | ! chair |
- | ! Partner | + | |
+ | ! co-chair | ||
+ | |||
+ | ! Partner(s) | ||
|- | |- | ||
- | | [[Task Force I]] | + | | [[Task Force I|Task Force I]] |
+ | |||
| Mass-spectrometric and chromatographic methods andpreanalytics for molecular lipid species analyses and stable isotope labelling | | Mass-spectrometric and chromatographic methods andpreanalytics for molecular lipid species analyses and stable isotope labelling | ||
- | | Micheal Wakelam | + | |
- | | [[User: | + | | [[User:Michael Wakelam|Prof. Micheal Wakelam]] |
- | | [[ | + | |
- | + | | [[User:Gerhard Liebisch|PhD. Gerhard Liebisch]] | |
+ | |||
+ | | [[P01 UHREG|P01]], [[P02 UU|P02]], [[P04 INSERM|P04]], [[P06 ETHZ|P06]], [[P07 UNIGRAZ|P07]], [[P11 BRC HAS|P11]], [[P13 BABRAHAM|P13]], [[P14 UH|P14]], [[P15A UBO|P15A]], [[P15B UBO|P15B]], [[P17 UMG GOE|P17]], [[P18 BIOBASE|P18]], [[P19 ZORA|P19]], [[P21 INTEGROMICS|P21]], [[P22 UOXF.H7|P22]], [[P25 ISB|P25]] | ||
|- | |- | ||
- | | [[Task Force II]] | + | | [[Task Force II|Task Force II]] |
+ | |||
| Fluorescence-based lipidomic methods on intact cells, labelling lipidomic antibodies and proteins | | Fluorescence-based lipidomic methods on intact cells, labelling lipidomic antibodies and proteins | ||
- | | | + | |
- | | | + | | [[User:Christoph Thiele|Dr. Christoph Thiele]] |
- | | P01, P04, P09, | + | |
- | + | | [[User:Aldona Dembinska-Kiec|Prof. Dr. Aldona Dembinska-Kiec]] | |
+ | |||
+ | | [[P01 UHREG|P01]], [[P04 INSERM|P04]], [[P09 JUMC|P09]], [[P11 BRC HAS|P11]], [[P13 BABRAHAM|P13]], [[P14 UH|P14]], [[P15B UBO|P15B]], [[P23 MRC|P23]], [[P24 JKU|P24]] | ||
|- | |- | ||
- | | [[Task Force III]] | + | | [[Task Force III|Task Force III]] |
+ | |||
| Affinity binder, ELISA and proteomic mass-spectrometric techniques and reagents | | Affinity binder, ELISA and proteomic mass-spectrometric techniques and reagents | ||
- | | | + | |
- | | | + | | [[User:Stefan Müllner|Dr. Stefan Müllner]] |
- | | P01, | + | |
- | + | | Dr. Stefan Wallner | |
+ | |||
+ | | [[P01 UHREG|P01]], [[P07 UNIGRAZ|P07]], [[P16 EMBL|P16]], [[P20 PROTAGEN|P20]] | ||
|- | |- | ||
- | | [[Task Force IV]] | + | | [[Task Force IV|Task Force IV]] |
+ | |||
| Gene-, Taqman- and Bead-array reagents and preanalytics (RNA/DNA, Agilent, Affymetrix, Illumina, ABI TLDAs etc) | | Gene-, Taqman- and Bead-array reagents and preanalytics (RNA/DNA, Agilent, Affymetrix, Illumina, ABI TLDAs etc) | ||
- | | | + | |
- | | | + | | [[User:Gerd Schmitz|Prof. Dr. Gerd Schmitz]] |
- | | P01, | + | |
- | + | | [[User:Christian Wolfrum|Dr. Christian Wolfrum]] | |
+ | |||
+ | | [[P01 UHREG|P01]], [[P06 ETHZ|P06]], [[P09 JUMC|P09]] | ||
|- | |- | ||
- | | [[Task Force V]] | + | | [[Task Force V|Task Force V]] |
+ | |||
| Mouse models | | Mouse models | ||
- | + | ||
- | | | + | | [[User:Christian Wolfrum|Dr. Christian Wolfrum]] |
- | | | + | |
- | + | | Van Dijk | |
+ | |||
+ | | [[P02 UU|P02]], [[P03 CMNS|P03]], [[P04 INSERM|P04]], [[P05 LUMC|P05]], [[P06 ETHZ|P06]], and [[P07 UNIGRAZ|P07]] | ||
|- | |- | ||
- | | [[Task Force VI]] | + | | [[Task Force VI|Task Force VI]] |
+ | |||
| Clinical trials and human ethics | | Clinical trials and human ethics | ||
- | + | ||
- | | | + | | [[User:Daniela Gasperikova|Dr. Daniela Gasperikova]] |
- | | | + | |
- | + | | [[User:Frederik Karpe|Dr. Fredrik Karpe]] | |
+ | |||
+ | | [[P01 UHREG|P01]], [[P08 UGOT|P08]], [[P09 JUMC|P09]], [[P11 BRC HAS|P11]], [[P12 IEE SAS|P12]], [[P13 BABRAHAM|P13]], [[P14 UH|P14]], [[P15A UBO|P15A]], [[P15B UBO|P15B]], [[P22 UOXF.H7|22]], [[P23 MRC|P23]], and [[P24 JKU|P24]] | ||
|- | |- | ||
! Horizontal Task Forces | ! Horizontal Task Forces | ||
- | + | ||
- | ! | + | ! <br> |
- | ! | + | |
- | ! | + | ! <br> |
- | + | ||
+ | ! <br> | ||
+ | |||
+ | ! <br> | ||
|- | |- | ||
- | | [[Task Force VII]] | + | | [[Task Force VII|Task Force VII]] |
+ | |||
| Human/Mouse translational research | | Human/Mouse translational research | ||
- | | | + | |
- | | | + | | [[User:Gerd Schmitz|Prof. Dr. Gerd Schmitz]] |
- | | P01, P04, P06, P12, P13, | + | |
- | + | | [[User:Isabelle Dugail|Dr. Isabelle Dugail]] | |
+ | |||
+ | | [[P01 UHREG|P01]], [[P04 INSERM|P04]], [[P06 ETHZ|P06]], [[P12 IEE SAS|P12]], [[P13 BABRAHAM|P13]], [[P15A UBO|P15A]] | ||
|- | |- | ||
- | | [[Task Force VIII]] | + | | [[Task Force VIII|Task Force VIII]] |
- | | LipidomicNet-Bioinformatics | + | |
- | | | + | | LipidomicNet-Bioinformatics |
- | | | + | |
- | | P01, P06, P10, P16, P17, P18, P21, P22, P25 | + | | [[User:Juan Antonio Vizcaíno|Dr. Juan_Antonio_Vizcaíno]] |
- | + | ||
- | + | | [[User:Gerd Schmitz|Prof. Dr. Gerd Schmitz]] | |
+ | |||
+ | | [[P01 UHREG|P01]], [[P06 ETHZ|P06]], [[P10 MPG|P10]], [[P16 EMBL|P16]], [[P17 UMG GOE|P17]], [[P18 BIOBASE|P18]], [[P21 INTEGROMICS|P21]], [[P22 UOXF.H7|P22]], [[P25 ISB|P25]] | ||
|- | |- | ||
- | | [[Task Force IX]] | + | | [[Task Force IX|Task Force IX]] |
+ | |||
| Dissemination, training and communication | | Dissemination, training and communication | ||
- | | | + | |
- | | | + | | [[User:Aldona Dembinska-Kiec|Prof. Dr. Aldona Dembinska-Kiec]] |
+ | |||
+ | | [[User:Megi Sharikadze|Dr. Megi Sharikadze]] | ||
+ | |||
| All partners | | All partners | ||
|} | |} | ||
- | <div style="border: 1px solid red; font-weight: bold | + | <div style="border: 1px solid red; padding: 3px; font-weight: bold; margin-right: 10px;">Together the specialized vertical and the integrative horizontal Task Forces (TFs) will generate maximal integration and efficient dissemination and training.</div> |
- | generate maximal integration and efficient dissemination and training.</div> | + | |
- | + | [[Category:Task_Forces]] | |
- | [[Category: | + |
Current revision
The LipidomicNet consortium consists of six vertical (TFI-VI) and three horizontal integrative (TFVII-TFIX) task forces.
Specific enabling technologies and their applications (TF I-IV).
Mouse models (TF V).
Human clinical trials and ethics issues (TF VI).
Translational research (TF VII).
LipidomicNet (TF VIII).
Dissemination and training (TF IX).
Overview of LipidomicNet Task Forces
The following table shows an overview of the task forces their Leaders and corresponding LipidomicNet partners.
Vertical Task Forces | Taskforce | chair | co-chair | Partner(s) |
---|---|---|---|---|
Task Force I | Mass-spectrometric and chromatographic methods andpreanalytics for molecular lipid species analyses and stable isotope labelling | Prof. Micheal Wakelam | PhD. Gerhard Liebisch | P01, P02, P04, P06, P07, P11, P13, P14, P15A, P15B, P17, P18, P19, P21, P22, P25 |
Task Force II | Fluorescence-based lipidomic methods on intact cells, labelling lipidomic antibodies and proteins | Dr. Christoph Thiele | Prof. Dr. Aldona Dembinska-Kiec | P01, P04, P09, P11, P13, P14, P15B, P23, P24 |
Task Force III | Affinity binder, ELISA and proteomic mass-spectrometric techniques and reagents | Dr. Stefan Müllner | Dr. Stefan Wallner | P01, P07, P16, P20 |
Task Force IV | Gene-, Taqman- and Bead-array reagents and preanalytics (RNA/DNA, Agilent, Affymetrix, Illumina, ABI TLDAs etc) | Prof. Dr. Gerd Schmitz | Dr. Christian Wolfrum | P01, P06, P09 |
Task Force V | Mouse models | Dr. Christian Wolfrum | Van Dijk | P02, P03, P04, P05, P06, and P07 |
Task Force VI | Clinical trials and human ethics | Dr. Daniela Gasperikova | Dr. Fredrik Karpe | P01, P08, P09, P11, P12, P13, P14, P15A, P15B, 22, P23, and P24 |
Horizontal Task Forces | | | | |
Task Force VII | Human/Mouse translational research | Prof. Dr. Gerd Schmitz | Dr. Isabelle Dugail | P01, P04, P06, P12, P13, P15A |
Task Force VIII | LipidomicNet-Bioinformatics | Dr. Juan_Antonio_Vizcaíno | Prof. Dr. Gerd Schmitz | P01, P06, P10, P16, P17, P18, P21, P22, P25 |
Task Force IX | Dissemination, training and communication | Prof. Dr. Aldona Dembinska-Kiec | Dr. Megi Sharikadze | All partners |
Together the specialized vertical and the integrative horizontal Task Forces (TFs) will generate maximal integration and efficient dissemination and training.